After last year’s recall of valsartan tablets, the FDA has prioritized the approval of a new generic form of the angiotensin II receptor blocker to address the drug shortage.
The FDA issued an alert regarding the safety of tofacitinib following the results of a clinical trial that showed increased risk of pulmonary embolism.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has called for the addition of a Boxed Warning alerting clinicians and patients of an increased risk of cardiovascular death with the use of a drug used for the treatment of gout.
The FDA has issued new proposed regulations for over-the-counter sunscreens marketed in the United States updating regulatory requirements to ensure consumers have access to safe and effective sun...
